BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.
Benzinga ·